{"id":"clazosentan","rwe":[{"pmid":"41882452","year":"2026","title":"Cost-utility framework to evaluate therapeutic interventions targeting reduction in cerebral infarction among aneurysmal subarachnoid hemorrhage patients.","finding":"","journal":"Neurosurgical review","studyType":"Clinical Study"},{"pmid":"41874921","year":"2026","title":"Early Positive Fluid Balance as a Clinical Marker of Systemic Capillary Leak and Clazosentan Intolerance After Aneurysmal Subarachnoid Hemorrhage.","finding":"","journal":"Neurocritical care","studyType":"Clinical Study"},{"pmid":"41866641","year":"2026","title":"The beneficial effects of clazosentan on the perioperative management of patients with subarachnoid hemorrhage.","finding":"","journal":"Neurosurgical review","studyType":"Clinical Study"},{"pmid":"41753071","year":"2026","title":"Machine Learning-Identified Potential Interaction Between Clazosentan and Nicardipine in Patients with Subarachnoid Hemorrhage.","finding":"","journal":"Journal of clinical medicine","studyType":"Clinical Study"},{"pmid":"41481629","year":"2026","title":"A simulation study of the cost of cerebral vasospasm treatments with clazosentan: A mathematical model using time-driven activity-based costing.","finding":"","journal":"PloS one","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Endothelin-1 receptor","category":"target"},{"label":"EDNRA","category":"gene"},{"label":"EDNRB","category":"gene"},{"label":"Active","category":"status"},{"label":"Prevention of cerebrovascular spasm","category":"indication"},{"label":"Idorsia Pharmaceuticals Japan Ltd","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Idorsia Pharmaceuticals Japan Ltd","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CLAZOSENTAN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:12:27.909719+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Clazosentan","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:12:34.700314+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:12:33.003571+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CLAZOSENTAN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:12:33.652337+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5314590/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:12:34.352263+00:00"}},"allNames":"pivlaz","offLabel":[],"synonyms":["clazosentan","clazosentan sodium","pivlaz","Ro 61-1790","AXV-034343","VML 588","ACT-108475"],"timeline":[{"date":"2022-01-20","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Idorsia Pharmaceuticals Japan Ltd)"}],"approvals":[{"date":"2022-01-20","orphan":false,"company":"IDORSIA PHARMACEUTICALS JAPAN LTD","regulator":"PMDA"}],"brandName":"Pivlaz","ecosystem":[{"indication":"Prevention of cerebrovascular spasm","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Endothelin-1 receptor","targets":[{"gene":"EDNRA","source":"DrugCentral","target":"Endothelin-1 receptor","protein":"Endothelin-1 receptor"},{"gene":"EDNRB","source":"DrugCentral","target":"Endothelin B receptor","protein":"Endothelin B receptor"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Pivlaz is a selective endothelin receptor antagonist (ETA), specifically targeting the ETA receptor subtype. By blocking the ETA receptor, Pivlaz inhibits the vasoconstrictive effects of endothelin-1, leading to vasodilation and a reduction in cerebrovascular spasm."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Clazosentan","title":"Clazosentan","extract":"Clazosentan is a drug belonging to the class of endothelin receptor antagonists."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5518","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CLAZOSENTAN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CLAZOSENTAN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Clazosentan","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T10:09:26.838254","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:12:36.084005+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"ambrisentan","drugSlug":"ambrisentan","fdaApproval":"2007-06-15","patentExpiry":"Oct 14, 2031","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"bosentan","drugSlug":"bosentan","fdaApproval":"2001-11-20","patentExpiry":"May 15, 2026","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"macitentan","drugSlug":"macitentan","fdaApproval":"2013-10-18","patentExpiry":"Sep 11, 2026","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"sulfafurazole","drugSlug":"sulfafurazole","fdaApproval":"1971-06-07","relationship":"same-target"},{"drugName":"sulfisoxazole acetyl","drugSlug":"sulfisoxazole-acetyl","fdaApproval":"1953-12-04","patentStatus":"Unknown","relationship":"same-target"}],"genericName":"clazosentan","indications":{"approved":[{"name":"Prevention of cerebrovascular spasm","source":"DrugCentral","snomedId":73173006,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"ambrisentan","brandName":"ambrisentan","genericName":"ambrisentan","approvalYear":"2007","relationship":"same-target"},{"drugId":"bosentan","brandName":"bosentan","genericName":"bosentan","approvalYear":"2001","relationship":"same-target"},{"drugId":"macitentan","brandName":"macitentan","genericName":"macitentan","approvalYear":"2013","relationship":"same-target"},{"drugId":"sulfafurazole","brandName":"sulfafurazole","genericName":"sulfafurazole","approvalYear":"1971","relationship":"same-target"},{"drugId":"sulfisoxazole-acetyl","brandName":"sulfisoxazole acetyl","genericName":"sulfisoxazole acetyl","approvalYear":"1953","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT03585270","phase":"PHASE3","title":"Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2019-02-03","conditions":["Aneurysmal Subarachnoid Hemorrhage"],"enrollment":409,"completionDate":"2022-11-18"},{"nctId":"NCT00558311","phase":"PHASE3","title":"Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2007-12-14","conditions":["Aneurysmal Subarachnoid Hemorrhage"],"enrollment":1157,"completionDate":"2010-07-13"},{"nctId":"NCT03657446","phase":"PHASE1","title":"A Study in Healthy Subjects to Investigate Whether Administration of Clazosentan Can Affect Normal Heart Function","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2018-09-18","conditions":["Healthy Subjects"],"enrollment":36,"completionDate":"2018-10-26"},{"nctId":"NCT03596294","phase":"PHASE1","title":"A Study in Healthy Male Subjects to Investigate Whether Administration of Rifampicin Can Affect the Fate of Clazosentan in the Body of Clazosentan","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2018-07-19","conditions":["Healthy Subjects"],"enrollment":14,"completionDate":"2018-08-03"},{"nctId":"NCT00111085","phase":"PHASE2","title":"Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2005-01-10","conditions":["Aneurysmal Subarachnoid Hemorrhage"],"enrollment":413,"completionDate":"2006-03-30"},{"nctId":"NCT02560532","phase":"PHASE2","title":"Evaluation of the Efficacy and Safety of Clazosentan in Reversing Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2016-03-01","conditions":["Aneurysmal Subarachnoid Hemorrhage"],"enrollment":25,"completionDate":"2017-05-02"},{"nctId":"NCT00940095","phase":"PHASE3","title":"Clazosentan in Aneurysmal Subarachnoid Hemorrhage","status":"TERMINATED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2009-07-01","conditions":["Aneurysmal Subarachnoid Hemorrhage"],"enrollment":577,"completionDate":"2011-01-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"3DRR0X4728","INN_ID":"8397","UMLSCUI":"C1721268","chemblId":"CHEMBL5314590","ChEMBL_ID":"CHEMBL109648","KEGG_DRUG":"D11664","DRUGBANK_ID":"DB06677","PUBCHEM_CID":"6433095","IUPHAR_LIGAND_ID":"12286","SECONDARY_CAS_RN":"503271-02-1","MESH_SUPPLEMENTAL_RECORD_UI":"C109641"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Idorsia Pharmaceuticals Japan Ltd","relationship":"Current Owner"}],"publicationCount":167,"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 26","pmid":"41882452","title":"Cost-utility framework to evaluate therapeutic interventions targeting reduction in cerebral infarction among aneurysmal subarachnoid hemorrhage patients.","journal":"Neurosurgical review"},{"date":"2026 Mar 24","pmid":"41874921","title":"Early Positive Fluid Balance as a Clinical Marker of Systemic Capillary Leak and Clazosentan Intolerance After Aneurysmal Subarachnoid Hemorrhage.","journal":"Neurocritical care"},{"date":"2026 Mar 23","pmid":"41866641","title":"The beneficial effects of clazosentan on the perioperative management of patients with subarachnoid hemorrhage.","journal":"Neurosurgical review"},{"date":"2026 Feb 10","pmid":"41753071","title":"Machine Learning-Identified Potential Interaction Between Clazosentan and Nicardipine in Patients with Subarachnoid Hemorrhage.","journal":"Journal of clinical medicine"},{"date":"2026","pmid":"41481629","title":"A simulation study of the cost of cerebral vasospasm treatments with clazosentan: A mathematical model using time-driven activity-based costing.","journal":"PloS one"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Idorsia Pharmaceuticals Japan Ltd","companyId":"idorsia-pharmaceuticals-japan-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pivlaz, also known as clazosentan, is a small molecule. It is being studied in clinical trials for the treatment of aneurysmal subarachnoid hemorrhage.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2022-01-20T00:00:00.000Z","mah":"IDORSIA PHARMACEUTICALS JAPAN LTD","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Pivlaz","application_number":"Pivlaz"}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:12:36.084005+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}